Recently, the phase 1 study of the dual MDM2/MDMX inhibitor ALRN-6924 in pediatric cancer demonstrated safety, tolerability, and promising antitumor activity in relapsed or refractory solid tumors and acute lymphoblastic leukemia. This evidence concerns the gene MDM2 and cancer.